Active, not recruitingPhase 2NCT04550481

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Studying Fibrolamellar hepatocellular carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Northwestern University
Principal Investigator
Ju Dong Yang
Northwestern University
Intervention
Biospecimen Collection(procedure)
Enrollment
45 enrolled
Eligibility
18 years · All sexes
Timeline
20212026

Study locations (4)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04550481 on ClinicalTrials.gov

Other trials for Fibrolamellar hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Fibrolamellar hepatocellular carcinoma

← Back to all trials